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Abstract
Primaquine was officially licensed as an anti-malarial drug by the FDA in 1952. It has remained the only FDA
licensed drug capable of clearing the intra-hepatic schizonts and hypnozoites of Plasmodium vivax. This update
and review focuses on five major aspects of primaquine use in treatment of vivax malaria, namely: a) evidence of
efficacy of primaquine for its current indications; b) potential hazards of its widespread use, c) critical analysis of
reported resistance against primaquine containing regimens; d) evidence for combining primaquine with
artemisinins in areas of chloroquine resistance; and e) the potential for replacement of primaquine with newer
drugs.
Keywords: Primaquine, Plasmodium vivax, Vivax Malaria, Prophylaxis, Radical cure
Introduction
Primaquine, an 8-aminoquinoline, has been approved
for treatment of malaria since 1952 by the Food and
Drug Administration (FDA), United States [1]. Six dec-
ades after its official licensing, primaquine still holds a
unique and unchallenged place in anti-malarial regimens
of cure and prophylaxis [2]. It is the only drug proven
to be effective, and licensed to eliminate, the hypno-
zoites of Plasmodium vivax and Plasmodium ovale.
Though primaquine is effective, unique and irreplace-
able, it is also associated with serious hazards and side
effects, such as its ability to precipitate haemolysis in
glucose-6-phosphate dehydrogenase (G6PD) deficient
individuals [3]. This prohibits its use in key groups, such
as pregnant women [4]. The current uses of primaquine
in vivax malaria are threefold: for radical cure of
patients with confirmed parasitaemia; for causal prophy-
laxis; and for terminal prophylaxis [1]. In addition, it is
used as a gametocytocidal agent in falciparum malaria.
This update and review deals with the current role of
primaquine in treatment of vivax malaria. It will explore
this topic on several fronts namely: a) evidence of effi-
cacy of primaquine for its current indications; b) poten-
tial hazards of its widespread use c) critical analysis of
reported resistance against primaquine containing regi-
mens d) evidence for combining primaquine with arte-
misinins in areas of chloroquine resistance and e) the
potential for replacement of primaquine with newer
drugs.
Methods
A MEDLINE search was performed for all articles with
the key word ‘primaquine’ and ‘Vivax’ in any field. The
search was restricted to articles published in all lan-
guages within the last two decades (1991-2011). There
were 480 abstracts in the original search with these
restrictions. The software Endnote X3 (Thomson Reu-
ters, Carlsbad, CA 92011, USA) was used to filter arti-
cles. Bibliographies of cited literature were also
searched. All abstracts were read independently by the
three authors, and key articles were identified based on
a consensus among all authors. Ninety two articles
(including 40 clinical trials and 14 reviews) were
selected for the final synthesis based on the relevance to
the topic. The search was restricted to the last two dec-
ades to avoid redundant data and to select more recent
evidence. However, related or cited papers of crucial
trials before this period have also been included. Other
papers included were case reports, opinion papers, treat-
ment guidelines, experimental laboratory studies and
cross sectional analyses of endemic populations. The
epidemiological data and guidelines for treatment were
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Primaquine: Indications and efficacy
Primaquine has a unique and powerful role in the pre-
vention and cure of malaria. It is the only FDA licensed
drug that can destroy all liver stages (hypnozoites and
schizonts) of the parasite. The drug has been licensed
for use since the 1950s, though its mechanism of action
is not yet fully understood. It is thought to interfere
with the cellular respiration of the parasite by generating
oxygen free radicals and deregulating the electron trans-
port [1].
Before detailing the trial evidence on the efficacy of
primaquine for its different indications, we would like to
emphasize several issues that need to be remembered
when interpreting data. Primaquine is not administered
in isolation. It is co-administered with a blood schizon-
tocidal agent and the total effect is a reflection of the
synergistic efficacy of the schizontocidal agent and pri-
maquine. Similarly, reported efficacy (or lack of it)
depends on many other confounding factors such as the
geographical region in which the trials have been con-
ducted (equatorial, oceania or temperate regions), local
strains of P. vivax, drug compliance, appropriate dosing
according to bodyweight, duration of follow up, inability
to differentiate re-infection from a relapse (indicating
treatment failure), and small numbers in trial arms.
Furthermore, results gained from controlled trial condi-
tions may not be applicable when the drug is adminis-
tered to the population, especially with regard to
compliance. In determining the side effect profile, many
trials have filtered out G6PD deficient individuals
through initial screening; this may not always be possi-
ble with mass drug administration. These issues are dis-
cussed in detail in the relevant sections below.
The traditional indications for primaquine in vivax
malaria are threefold [1]: primary prophylaxis, terminal
prophylaxis, and radical cure.
Primary prophylaxis
Since the parasite must successfully complete its hepatic
stage before entering the erythrocytic stage, primaquine
is the ideal agent to use as primary (causal) prophylaxis
against P. vivax and ovale species. It is recommended
that 0.5 mg base/kg/d of primaquine (maximum 30 mg
per day) should be started one day before exposure and
continued daily till seven days after the end of exposure
[1]. Four randomized placebo-controlled trials in Asia
and South America have established the efficacy of pri-
maquine for this indication (i.e., primary prophylaxis
against vivax malaria) to be over 85%. Baird et al. in a
non-randomized open label trial in Irin Jaya, Indonesia
assessed the prophylactic efficacy of 0.5 mg/kg/d of pri-
maquine administered every other day against weekly
chloroquine 5 mg base/kg for 16-19 weeks [5]. The pro-
tective efficacy of the primaquine arm for vivax malaria
was over 90%. These findings were confirmed in another
placebo-controlled double b l i n dr a n d o m i z e ds t u d y ,
which showed the protective efficacy of primaquine (for
vivax malaria) to be 93% with a significantly lower infec-
tion rate compared to placebo [6]. A third placebo-con-
trolled double blind study in the same locality showed
similar prophylactic efficacy of primaquine against vivax
malaria [7]. Soto et al. assessed the protective efficacy of
primaquine 30 mg/d against a placebo in non-immune
Colombian soldiers and found it to have 85% efficacy in
preventing vivax malaria [8].
While all these trials demonstrate an impressive effi-
cacy rate of causal prophylaxis, it must be noted that all
were small-scale trials (largest number in a treatment
arm was 126 patients). Three out of four trials have
been conducted in the same geographical area in Indo-
nesia, and show similar results of high efficacy. This
obviously raises doubts of its application to other geo-
graphical areas which may have different parasitic
strains. In fact, in the Colombian study, even when they
accounted for symptomatic cases of malaria (not parasi-
taemia), the protective efficacy was only 85%. It is nota-
ble that the situation in Africa is totally unaccounted for
except for a retrospective study of Israeli travellers to
Ethiopia. In this study, Schwartz et al. report almost
100% protective efficacy of primaquine 30 mg/d prophy-
lactic dosing to prevent vivax malaria, which was signifi-
cantly better than that of doxycycline or mefloquine [9].
H o w e v e r ,t h ep r o t e c t i v ee f f i c a c yi nA f r i c ai sy e tt ob e
assessed in a prospective randomized controlled trial.
Limited trial data, hazards of side effects, and the cost
effectiveness of administration (prevention of malaria vs.
costs of assessing the G6PD enzyme status) make pri-
maquine an undesirable agent for causal prophylaxis at
the moment. It is not currently licensed for this indica-
tion. However, when recipients are intolerant of other
prophylactic medications, primaquine can be used as an
alternative in non-G6PD deficient individuals [1].
Terminal prophylaxis
Primaquine is suggested to have a role in terminal pro-
phylaxis, i.e., medication taken towards the end of the
exposure period. This is based on the hypothesis that, in
vivax malaria, relapses occur due to liver hypnozoites
and a dose of primaquine should be administered to
clear this hepatic reservoir to avoid relapses. The cur-
rently recommended dose for this purpose is also 0.5
mg base/kg/d (maximum of 30 mg/d) for 14 days which
should overlap with a blood schizontocidal agent [1].
Chloroquine and primaquine are usually used in combi-
nation for this purpose [10] on the premise that chloro-
quine enhances the hypnozoite clearance of primaquine.
However, Soto et al. have demonstrated that the
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to the protective efficacy against falciparum malaria, or,
more surprisingly, against vivax malaria (as P. vivax was
sensitive to chloroquine in this locality) when compared
with primaquine alone [8,11]. Though the trial was car-
ried out in a limited number of (< 200) individuals in
Colombia, this interesting aspect has not been examined
in detail by anyone else. In our opinion, the role of pri-
maquine in terminal prophylaxis (in adult, non-immune,
non-pregnant travellers) needs to be re-assessed with
regard to cost and benefit. Even if the costs of testing
for G6PD status are included, it might prove cost-effec-
tive in preventing local outbreaks in non-immune com-
munities which result from relapse infections occurring
in travellers returning home from malaria endemic
areas. However it is noted that it may be impossible to
screen each and every traveler visiting a malarial area
for G6PD status. The benefit of primaquine terminal
prophylaxis can be improved if it is administered to
individuals with an intense and prolonged exposure to
vivax malaria. Currently there are no guidelines on this.
Radical cure
The third indication for primaquine is that of radical
cure [1]. Primaquine at a dose of 0.5 mg base/kg/d in
two divided daily doses (maximum of 30 mg/d) for 14
days is a better recommendation to clear the liver hyp-
nozoites when given together with a blood schizontoci-
dal agent. Shorter courses of primaquine (5 days
therapy) and lower doses (15 mg/d) have been shown to
be ineffective in preventing relapses [12-17]. These stu-
dies were conducted in India, Sri Lanka, the Brazilian
Amazon, Colombia and Afghan refugee camps in Paki-
stan, and had follow up periods from three months to
one year. Until recently, the recommended dose for
radical cure with primaquine was 15 mg/d for 14 days
(in combination with chloroquine). This dose was
agreed upon after observing the historical data of US
soldiers returning from the Korean War and also taking
in to account that primaquine at this dose was less likely
to precipitate a haemolytic crisis with G6PD deficiency
[1]. However experimental studies with different strains
of Plasmodium have shown that the dose of 15 mg/d is
ineffective in preventing relapses [1]. Furthermore, there
have been multiple reports of treatment failure from
various parts of the world where the older regimen of
primaquine had been administered, although some of
these may be due to poor compliance (data from Korean
peninsula, Afghanistan, India, Vietnam, Thailand)
[18-21]. Still, it had been shown that for individuals
with a higher bodyweight (> 70 kg), a 15 mg/d prima-
quine dose was ineffective in preventing relapses even
with good compliance [1,22]. Therefore the current
recommendation of the Center for Disease Control
(CDC), USA for use of primaquine for radical cure
stands at 0.5 mg/kg/d for 14 days (maximum of 30 mg/
d) [1]. Nonetheless, the World Health Organization
recommends a dose of 0.25 mg/kg/d for 14 days except
in Oceania and Southeast Asia [23]. Though the recom-
mendation is such, the WHO acknowledges that prima-
quine in doses from 0.25 to 0.75 mg/kg/d are effective
for radical cure when given for 14 days. The reason for
recommending the lower dose may be the concern
about possible precipitation of G6PD deficiency with
higher doses. Still, with the popularization with cheaper
methods for screening of G6PD deficiency (see below)
and with reported cases of treatment failure with the
lower doses (0.25 mg/kg/d), we suggest the 0.5 mg/kg/d
dosing to be more appropriate for the radical cure of
uncomplicated vivax malaria.
Finally, primaquine can be used to prevent the trans-
mission of falciparum malaria. In patients treated with
chloroquine or artesunate, terminal dosing with prima-
quine is effective in eradicating circulating gameto-
cytes, which are infective to the vector/s [24]. Thus, it
acts as a chemoprophylactic agent at the community
level by interrupting the transmission of falciparum
malaria. Interestingly, this has an impact on preventing
cases of vivax malaria as well. The appearance of vivax
infections following uncomplicated falciparum infec-
tions has been observed and reported by several
authors [25-27]. The occurrence has been frequently
noted in analysis of several patient cohorts of malaria
trials, and thus cannot be considered a random phe-
nomenon. Lin et al. have recently showed (in Cambo-
dia) that falciparum gametocytaemia at the time of
presentation of the febrile illness in uncomplicated fal-
ciparum infections is a marker of subsequent short-
term infection with P. vivax [25]. The authors propose
two theories in this regard. One is that in areas where
both infections predominate, infection with one para-
site means exposure to other as well. Therefore, a
patient harbouring falciparum infection (manifested)
may also have hypnozoites from a previous vivax infec-
tion as well (dormant). As the falciparum infection
clears, the vivax gets activated. Secondly, it is possible
that co- infection with a second parasite species (P.
vivax)p u s h e sP. falciparum t op r o v i d em o r eg a m e t o -
cytes (shift of the equilibrium from asexual to sexual
forms). Either way this confirms the place of prima-
quine in treatment regimens for falciparum infections.
H o w e v e r ,t h es t a n d a r d4 5m gs i n g l ed o s eg i v e nf o r
gametocyte clearance is not effective in preventing
subsequent vivax infections [26]. Some authors there-
fore recommend that a full course of primaquine
should be initiated after a risk stratification process (to
minimize risks and hazards of primaquine side effects)
to patients with falciparum infections living in areas
where both P. falciparum and P. vivax are found [25].
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The most feared complication of primaquine adminis-
tration is the precipitation of haemolysis in G6PD defi-
cient individuals. Primaquine may also cause clinically
non-significant haemolysis in non-G6PD deficient indi-
viduals as well. Other major side effects include;
methaemoglobinaemia, hypersensitivity reactions and
gastrointestinal disturbances [1]. In individuals without
G6PD deficiency, trial evidence indicates that prima-
quine is well tolerated in therapeutic doses with mini-
mum side effects. However, it is currently
contraindicated in G6PD deficiency, NADH methaemo-
globin reductase deficiency, known hypersensitivity to
primaquine and pregnancy as recommended by the
Center for Disease Control [1]. The recommendation by
the British Medical Association is also similar [28]. It is
considered safe for use in breastfeeding mothers as long
as the G6PD status of the infant is tested and known. It
is not recommended for use in children under 4 years
of age.
Though these contraindications exist on paper, in
practice, the issue is more complex. The exposed popu-
lation is extremely large in many endemic areas and
testing for G6PD status in all individual is a costly exer-
cise. Even testing in non-immune travellers returning
from endemic areas is a daunting task given the num-
bers involved. Therefore, in many resource-limited set-
tings, primaquine is prescribed without testing for
G6PD status. The phenotypes of G6PD deficiency itself
a r eh i g h l yv a r i a b l e ,w h i c hi sn o ts u r p r i s i n gs i n c et h e r e
are almost 300 different allelic mutations for this X
linked recessive disorder [1,29]. The mutations and pre-
valence of each mutation in a population determine the
risk of ‘blind’ administration of primaquine. For exam-
ple, G6PD deficiency is common among people of Afri-
can origin but the enzyme deficiency is relatively mild
(A
- variant) with most having greater than 10% of the
enzyme activity [30]. They are relatively resistant to ser-
ious reactions with primaquine-induced haemolysis.
However, among Caucasians and Asians, though the
prevalence of G6PD deficiency is less, the enzymatic
activity in homozygotes is relatively low leaving a sizable
proportion of deficient individuals vulnerable to serious
r e a c t i o n s[ 3 1 ] .T h ep r e v a l e n c eo fG 6 P Dd e f i c i e n c ya l s o
varies with the ethnic background. The Mediterranean
B
- variant prevalent in certain ethnic groups originating
in the Mediterranean and West Asia has minimal G6PD
activity. They are vulnerable to severe life threatening
haemolysis with primaquine [32].
Similar to sickle cell disease, the G6PD deficient states
may also confer resistance against infection by Plasmo-
dium sp. The rapid clearance and shorter half-life of red
cells in affected individuals may be responsible for this
effect. This phenomenon has been demonstrated for the
African A
- variant, showing that it confers protection
against lethal falciparum malaria [33,34].
Until recently, vivax malaria was not thought to confer
such a benefit. Vivax malaria was considered a benign
entity which could not exert a significant evolutionary
selection pressure. However, recent studies have shown
that in areas of vivax endemicity, G6PD deficiency
might offer protection against the infection [35].
Leslie et al.[35] in a case control study of Afghan refu-
gees showed that phenotypic G6PD deficiency was less
common in cases with vivax malaria than in controls
(1.1% vs. 5.7%). The adjusted odds ratio for hemizygous
G6PD deficient males (Mediterranean variant) to con-
tract vivax malaria was 0.12 (95% confidence interval
0.02-0.92, p = 0.041). Similarly, the adjusted odds ratio
for females (heterozygous or homozygous) was 0.37
(95% confidence interval 0.15-0.94, p = 0.037). Another
recent study has demonstrated that the G6PD Mahidol
variant in Thailand is associated with a low rate of para-
sitaemia in infected adults in Thailand [36]. If this
hypothesis of G6PD deficient states offering protection
against vivax malaria is true, then it brings forth a
dilemma. Assuming that most of the infected are unli-
kely to be G6PD deficient, prescribing primaquine may
be relatively safe for radical cure. However, because of
evolutionary selection, it might also indicate that the
endemic areas have proportionately more G6PD defi-
cient people, which might render non selective adminis-
tration of primaquine in prophylactic regimens more
dangerous. In some areas this proportion is estimated to
be as high as 30% [37]. There is considerable variation
between different ethnic groups, even if they are geogra-
phically close to each other. The estimated prevalence
of G6PD deficiency in Central Asia varies from 2.1% in
Tajikistan, 2.9% in Iran, 7.0% in Pakistani Pathans,
15.8% in Pakistani Pashtuns to as high as 36.4% in Azer-
baijan [29,31,38,39]. Therefore, liberal prescription of
primaquine cannot be carried out without assessing its
risks in ethnic groups with high G6PD deficiency rates.
Recommendations and precautions also have to vary
according to the population prevalence of the condition.
In addition to the genotypic and phenotypic variations
of the recipient, the dose of primaquine administered
also influences the severity of the outcome in cases of
G6PD deficiency. According to the current recommen-
dations, patients may receive 0.75 mg base/kg body
weight (45 mg stat dose) of primaquine for clearance of
gametocytes of P. falciparum or 30 mg (or 15 mg/d as
per WHO recommendation) daily doses for 14 days for
radical cure of P. vivax [23]. In patients without G6PD
deficiency, haemolysis is not observed even though pri-
maquine is taken in daily maximum therapeutic doses
for a prolonged period (up to 20 weeks in the trial by
Baird et al. in Indonesia) [6]. In situations of G6PD
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activity will determine the severity of the manifestations
of haemolysis. In mild deficiency states (African A
- var-
iant) the haemolysis is mild and starts 3-4 days after
exposure. The first to succumb are the aged red blood
cells and the patients seem to tolerate the standard
doses of primaquine after an initial episode of haemoly-
sis. In fact, a safer approach in these patients would be
to continue a weekly course of 45 mg of primaquine for
8 weeks and this has been demonstrated to be well tol-
erated without significant haemolysis [40-42]. More
recent studies in Thailand and Burma also indicate that
even in G6PD deficient individuals, massive haemolysis
was not observed with standard doses of primaquine
administration (45 mg stat doses and 15-30 mg daily for
14 days) [43-45]. However the numbers of G6PD defi-
cient patients in all these studies were small and did not
exceed 20. Nonetheless, these findings do not conclu-
sively indicate that non-specific administration of prima-
quine is safe. If mass administration is allowed, millions
of population will be exposed to the drug and the
response of different genotypic variants of G6PD defi-
cient individuals would be different. There may be
sporadic but significant number of cases of severe hae-
molysis, haemoglobinuria, acute kidney injury and asso-
ciated fatalities. This is especially true in certain
geographical areas which have high G6PD deficient
rates and in areas where the Mediterranean B
- variant is
prevalent.
It is highly recommended to check for G6PD defi-
ciency status in individuals before prescribing prima-
quine for terminal prophylaxis and in radical cure
regimens. It is further recommended that governments
in malaria endemic regions make an effort to quantify
G6PD deficiency rates in different ethnic groups as this
may be a long term investment in preventing prima-
quine induced adverse effects. Quantitative testing is
expensive but now a qualitative fluorescent spot test is
available which is sufficient to spot individuals with an
increased risk [46]. Primaquine administration in preg-
nancy should remain contraindicated as the G6PD state
of the foetus cannot be determined.
Methaemoglobinaemia is another consequence of pri-
maquine administration which is commonly identified
with therapeutic doses of primaquine; however, clinical
effects are not usually seen (except possibly in indivi-
duals with gas diffusion defects in lungs and those with
congenital NADH methaemoglobin reductase deficiency)
[1,47]. Methaemoglobinaemia is defined as a level of
more than 1% of the haemoglobin level [1]. Various stu-
dies have reported methaemoglobin levels up to 20%
without any symptoms with therapeutic doses of prima-
quine [6,48,49]. Methaemoglobin levels also seem to be
higher with higher doses of primaquine. The
relationship between the duration of therapy and
methaemoglobin levels is unclear. However, there must
be other confounding factors for development of
methaemoglobinaemia other than dose and duration, as
n o te v e r y o n es h o w sad o s eo rt i m ed e p e n d e n tr i s eo f
methaemoglobin levels following primaquine administra-
tion. In fact, this response is extremely variable. Again it
may be genetically determined and there is increasing
evidence that G6PD deficient individuals are more vul-
nerable to methaemoglobinaemia. However the evidence
is not yet clear in this regard. Santana et al. [50] showed
that in a group of patients developing methaemoglobi-
naemia following primaquine therapy, 51% were G6PD
deficient (G6PD deficiency in those without methaemo-
globinaemia was 8.7%). However, Ferreira et al. failed to
demonstrate a similar association [51].
The other side effects of primaquine include gastroin-
testinal disturbances and hypersensitivity reactions
(rare). In some, the gastrointestinal disturbances (nau-
sea, vomiting) can be severe affecting compliance. It is
recommended to take primaquine with food to avoid
these unpleasant side effects. In all clinical trials on pri-
maquine, it was well tolerated by most of the non-
G6PD deficient patients or volunteers [6,11].
It is interesting to note a recent finding of primaquine
induced differential gene expression in the liver with
exposure to the drug in high doses in mice [52]. This
study demonstrated that after being administered a sin-
g l ed o s eo fp r i m a q u i n ea t4 0m g / k g ,t h e r ew a sas u b s e -
quent deregulation of RNA expression corresponding to
several proteins involved in cellular processes such as
intracellular signaling, protein transport, haemopoiesis,
cell adhesion and proliferation. However, there were no
biochemical alterations of hepatic enzyme levels in
serum or microscopic histological abnormalities of liver
sections. This is a preliminary animal study which needs
to be explored further as consequences of long-term pri-
maquine exposure in humans are yet unknown.
Resistance to primaquine: Is it a major problem?
Primaquine has stood the test of time remarkably over
six decades since its introduction in anti-malaria treat-
ment. True treatment failure with primaquine is difficult
to define due to the confounding factors mentioned
below. However, it can be quoted as ‘recurrence of para-
sitaemia following administration of a previously effica-
cious regimen for that region’.R e s i s t a n c ef o r
primaquine mainly refers to its failure to clear the hepa-
tic stages (hypnozoites) of the P. vivax life cycle, as it is
not used as an erythrocytic schizontocidal agent.
Resistance to primaquine is a difficult entity to quan-
tify due to following reasons. Firstly, primaquine is not
used in isolation, it is combined with a blood schizonto-
cidal agent, and the lack of efficacy between the two
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efficacy of the standard chloroquine/primaquine regi-
men for confirmed cases of vivax malaria is due to the
blood schizontocidal activity of the former.
Secondly, the duration of therapy is important, as pri-
maquine is known to have a total dose effect on hypno-
zoites and hepatic schizonts of the parasite and shorter
courses of primaquine have been largely proven to be
ineffective. Therefore, failure reported in these instances
does not reflect a true failure of primaquine.
Thirdly, there are many different daily dosing regi-
mens that have been in use and the most popular was
the 15 mg/d for 14 days regimen. Nonetheless, treat-
ment success with this regimen was less than 100% in
many trials [54-56]. The failure rates were less when the
daily dose of primaquine was increased to 22.5 mg and
30 mg with the latter regimen having the highest effi-
cacy [18]. In another trial, Pukrittayakamee et al. [57]
report a higher efficacy in the treatment of acute P.
vivax infections and prevention of recrudescence with a
higher dose of primaquine (60 mg/d for 7 days com-
pared to 30 mg/d), up to 28 days of observation.
Fourthly, addressing issues such as adequate dosing
according to body weight and ensuring good compliance
is necessary before announcing treatment failure [58]. A
review of treatment failure with primaquine containing
regimens in different endemic areas have shown that
while adding primaquine to a blood schizontocidal
agent considerably reduced the rate of relapse, the pro-
tective effect was more with a higher total dose of pri-
maquine as well as a higher dose per body weight [59].
In some instances of reported failure with primaquine,
inadequate dosing compared to body weight of indivi-
duals was obvious [22,59,60]. It also questions the valid-
ity of earlier case reports of treatment failure with
primaquine containing regimens of 15 mg/d (or less
than 0.5 mg/kg/d) over 14 days [61-66]. Non compli-
ance is a serious problem with 14 day primaquine ther-
apy. In many studies, the adherence was shown to be
low even when a shorter course of primaquine was pre-
scribed [67]. After the symptoms abate, patients may
not complete the scheduled 14 days of treatment, espe-
cially because of gastrointestinal side effects. Takeuchi
et al. demonstrated in a trial in the Thai- Myanmar bor-
der region, that with directly observed therapy (DOT),
the compliance was better and the relapse rates were
less compared to self-administered therapy [58]. Non-
compliance with therapy was a major reason to push for
a shorter course of therapy. Given the massive numbers
involved, DOT may not be a feasible option in endemic
areas like Africa and Southeast Asia. However, in coun-
tries on the eve of eradication of malaria with very low
incidence rates, this may be a good option to execute
via the public health monitoring system (similar to the
surveillance and DOT of tuberculosis patients). For
example in Sri Lanka, DOT for patients with malaria is
already initiated. In other countries, the answer may lie
with the potential alternatives to primaquine like tafeno-
quine which can be administered over a shorter dura-
tion (see below).
Fifthly, gauging the risk of relapse with primaquine
failure is compounded by re-infection. The idea of radi-
cal cure with primaquine therapy is to remove hypno-
zoites that may cause treatment relapse. However, if the
patient remains in malaria endemic areas, he/she might
get re-infected with P. vivax again. This is not a treat-
ment failure of primaquine. Yet in trials which assessed
this aspect, there is little room to differentiate a relapse
from a re-infection. There is no experimental methodol-
ogy to assess the therapeutic efficacy of primaquine to
clear the intra-hepatocyte stages of the parasite,
although some researchers have made progress in this
aspect in developing an in vitro assay [68]. Similarly,
others have evaluated the possibility of including geno-
type analysis to differentiate between relapse and new
infections in trials. Sanchez et al.[69] observed high
rates of recurrences (up to 40% in 6 months) of P. vivax
infections in two cohorts of patients treated with chloro-
quine and primaquine (30 mg/d for 7 days only) in the
Brazilian Amazon. They performed genotyping in the P.
vivax isolates of the initial infections and of the recur-
rent infections. A recrudescence would be characterized
by the same genotype in both occasions and a new
infection by a different genotype. However, a relapse (by
activation of dormant forms) may be characterized by
non-identical but related genotypes in the second infec-
tion. Of 28 pairs analysed, only two showed identical
haplotypes and there were more non related haplotypes
than related haplotypes favouring re-infection over
recrudescence or relapse. However, interpretation and
validation of such data is yet to be standardized. In a
similar study where authors claim that the chances for
re-infection were minimized, the genotypes of the acute
and subsequent infections differed considerably [70].
This indicates three possibilities: a) several strains might
have been inoculated in to the patient during the expo-
sure period and each might have given rise to different
episodes; b) simultaneous inoculations may occur at the
time of initial bite by the mosquito; and c) high rates of
mutations and genetic re-assortment of the hepatic schi-
zonts may take place at the time of schizogony. What-
ever explanation is the most likely, it casts serious
doubts over the validity and usefulness of using geno-
typing to differentiate between a relapse and a re-
infection.
Most of the reports of ‘primaquine failure’ are in rela-
tion to using it in radical cure regimens (as it is not rou-
tinely recommended as a causal prophylactic agent). A
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rates as a terminal prophylactic agent. They assessed the
infection rate of vivax malaria in military personal being
administered chloroquine throughout the exposure per-
iod, and primaquine as terminal prophylaxis. This was
compared with the malaria incidence of soldiers not tak-
ing chemoprophylaxis. The rate of malaria did not differ
significantly between the two groups. The estimated effi-
cacy of primaquine as a terminal prophylactic agent was
as low as 32%. However, the design of the study raises
doubts about these figures. It is not clear when prophy-
laxis was administered and the time duration since pro-
phylaxis to infection. This is crucial as there is no
evidence as to how long the primaquine dose remains
effective and when the person is vulnerable to re-infec-
tions. It is also not clear whether cases and controls had
the same exposure to malaria for a valid comparison. If
the controls did not receive chemoprophylaxis it is likely
that their risk of exposure was less. The two groups
having the same rate of infections may partly be due to
new infections occurring after the chemoprophylactic
effect had worn off. There was also no way to verify
good compliance with the regimen as it was assessed
using retrospective recall. More importantly, the chemo-
prophylactic regimen used was that of 15 mg/d for 14
days, which is currently considered inadequate for com-
plete protection as per (CDC) recommendations.
A review by Baird et al. [71] of reported cases of pri-
maquine resistance over three decades showed some
interesting findings. A large number of reported treat-
ment failures were with the shorter courses of therapy
(15 mg/d for five days), which is considered ineffective.
The number of cases of treatment failure with 15 mg/d
for 14 days was considerably less. In most occasions of
resistance, compliance could not be verified accurately.
During the follow up period of 12 months, there was a
progressive reduction in numbers of relapses as the
daily primaquine dose increased (there were no relapses
when 30 - 60 mg/d were administered for 14 and 7
days, respectively). However, even when a high dose of
primaquine was administered without a concurrent schi-
zontocidal agent, the relapse rates were heavy (up to
80%) [72,73].
Nonetheless, the laps and inadequacies of previously
used primaquine regimens do not render primaquine
resistance a non-entity. Though it is extremely difficult
to establish true resistance, there are case reports of
recurring vivax malaria despite an adequate dose of pri-
maquine administered with an effective blood schizonto-
cidal agent [19]. Many of these reports were from the
Southeast Asian region and the resistance of the Ches-
s o ns t r a i no fP. vivax was an example of primaquine
failure in the early days [74]. However, this was during
the Second World War when there was mass migration
of soldiers and populations and when many experimen-
tal drugs with a structural resemblance to primaquine
were non-selectively distributed. In essence, the earlier
reports of the Chesson strain of P. vivax indicate the
potential for development of resistant strains when the
environmental conditions and selection pressure favour
it [1]. Even to date, failure with 15 mg/d for 14-day regi-
men is higher in travellers to Papua New Guinea (which
was the focal point in which Chesson strain was iso-
lated) than in other endemic areas [18].
Overall, a critical review of the reported instances of
primaquine ‘resistance’ raises serious doubts over their
validity with respect to design, adequacy of dosing, dura-
tion of treatment, risk of re-infection, non-compliance
with unsupervised treatment and small numbers of
patients in trials. It also indicates that success or failure
of treatment cannot be defined for primaquine alone. It
is more suitable to establish it with respect to the pri-
maquine dose, duration and the concurrent blood schi-
zontocidal agent administered, taken as a whole single
entity.
Primaquine with other blood schizontocidals against
vivax malaria
Chloroquine has been the backbone of vivax treatment
regimens since its inception and chloroquine together
with primaquine was the standard therapy for vivax
malaria on the understanding that P. vivax was univer-
sally sensitive to chloroquine. The first patient with
chloroquine resistant vivax malaria was reported from
Papua New Guinea in 1989 [75]. Since then cases have
been reported from a vast geographical area spanning
the continents of Asia (Indonesia, Myanmar, India, Tur-
key) [76-79], Africa (Ethiopia) [80] and South America
(Brazil, Peru, Colombia) [81-83]. In response, several
studies have evaluated the efficacy of primaquine with
Artemisinin based Combined Therapy (ACT).
Krudsood et al. [84] assessed the efficacy of arte-
mether-lumefantrine (each tablet containing 20 mg of
artemether and 120 mg of lumefantrine, 24 tablets to be
administered within 60 hours) vs. standard dose of
chloroquine against vivax malaria in a randomized open
labeled trial in Thailand. Both groups were given 15
mg/d primaquine for 14 days. Both regimens were
equally effective in clearing the infection with only one
treatment failure in the artemether-lumefantrine group.
The authors concluded that it is an effective alternative
to the current chloroquine based regimen. However,
there was no follow up beyond 28 days to detect any
relapses that would have assessed any impact on the
concurrently administered primaquine. Similar findings
were observed by Hamedi et al. [85] for artesunate and
primaquine combination against vivax malaria. In a
separate randomized trial, Krudsood et al. [86] assessed
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and high dose primaquine (administered for 5 groups as
30 mg a day for 5, 7, 9, 11, and 14 days. Group 6
received primaquine, 30 mg twice a day for 7 days). The
cure rates after 28 days of follow up were 100% and
96% for groups 5 and 6 respectively indicating the suc-
cess of high dose primaquine with artesunate over a
short observation period. The 60 mg/d dose was well
tolerated and its short duration was thought to improve
the compliance with the regimen, which is a major issue
with the 14-day course. Dao et al. [87] in a smaller
study (n-28) in Vietnam showed that artesunate (200
mg twice a day for 2 d) plus primaquine (22.5 mg base
twice a day for 7 d) was highly efficacious in clearing
the parasitaemia and ensuring cure at 28 days (only one
treatment failure was observed). Another trial in Thai-
land compared four treatment arms; oral artesunate 5
day course (200 mg on D1 and 100 mg daily for remain-
der), artesunate 7 day course in a dose as above, artesu-
nate 5 day course plus high dose primaquine (0.6 mg/
kg/d × 14 days), artesunate 7 day course and high dose
primaquine for 14 days [88]. The clinical response and
parasitic clearance was rapid and similar in all four
groups but almost 50% of participants who did not
receive primaquine had recurrence of parasitaemia by
D28. None of the patients who took primaquine had
recurrent parasitaemia up to D28. Similar results were
observed by Wilairatana et al. [20] who showed high
dose primaquine and artesuna t et ob es u p e r i o rt os u l -
phadoxine-pyrimethamine (SP), SP with high dose pri-
maquine and high dose primaquine alone in clearing
parasitaemia and avoiding recurrence up to 28 days.
Sinclair et al. [89] carried out a meta-analysis to assess
the efficacy of ACT against uncomplicated vivax
malaria. Of the 12 studies included in the analysis, only
four had been given primaquine in an adequate dose to
clear the hypnozoites. Even then, one trial had delayed
the administration of primaquine till D28 and another
had given an unsupervised primaquine course affecting
the validity of evidence. It was concluded that artemisi-
n i n sw i t hal o n g e rh a l f - l i f es uch as dihydroartemisinin-
piperaquine would provide a longer time of post treat-
ment prophylaxis (up to six weeks) compared to arte-
mether- lumefantrine even if concurrent primaquine
was not administered. However, the role of primaquine
with ACT cannot be elucidated from the trials men-
tioned in this meta-analysis.
Overall, it can be summarized that artemisinin-based
therapy is a successful alternative to chloroquine based
regimens in areas of vivax resistance. However artemisi-
nins alone may not be enough to clear the hepatic schi-
zonts and hypnozoites of P. vivax and, therefore, to
achieve radical cure, primaquine in high doses must be
added. The few trials available on these combinations
(all from Southeast Asia) show that primaquine in high
doses is safe, well tolerated and efficacious in preventing
parasitaemia up to 28 days since initiation of therapy.
Alternatives to primaquine: Can it be replaced?
Primaquine, despite being unique in its abilities, has sev-
eral major disadvantages. As pointed out earlier, its
potential to cause serious side effects of haemolysis in
G6PD deficient individuals is the most important con-
cern [1]. Its short half-life requires it to be administered
over a course of 14 days which leads to poor compliance
[58]. Circumventing this issue with shorter courses of
therapy has been largely unsuccessful.
Seeking a replacement for primaquine did not gather
momentum until recently due to several reasons. Many
did not consider vivax malaria to be a serious illness till
recent evidence proved otherwise (resistance to first line
treatment, increasing incidence and severity of illness).
The hunt for a replacement compound is also difficult
when the mechanism of action of primaquine itself is
obscure [18]. Furthermore, there is no proper in vivo or
vitro assay process to determine the efficacy of prima-
quine as a hypnozoitocidal. There has not been any con-
firmed identification of intra-hepatocyte forms of P.
vivax though some authors believe that they have been
able to grow them in vitro cell cultures [68].
There are several alternative compounds that have
been tested in various stages of clinical trials as a repla-
cement for primaquine (tafenoquine, bulaquine, tinida-
zole and inidazolidinone) [90]. Bulaquine is the pro-
drug of primaquine and is currently not licensed to be
used outside India. Data on its safety with widespread
use is not yet available [90]. Tafenoquine is a compound
that has shown some promise when used in a shorter
course of therapy of 3 days. It is also an 8-aminoquino-
line as primaquine. Walsh et al. [56] in a randomized
trial compared three different doses of tafenoquine (300
mg/d for 7 days, 600 mg/d for 3 days and 600 mg single
dose) given one day after a blood schizontocidal treat-
ment (chloroquine) in patients with vivax malaria. Addi-
tionally, these groups were compared with patients who
received chloroquine alone and chloroquine with low
dose primaquine (15 mg/d for 14 days). The protective
efficacy of tafenoquine was significantly greater com-
pared to other regimens up to eight weeks of follow up.
A larger, open-label, randomized, parallel-group study
by Elmes et al. [91] in Australian defense force person-
nel returning from Timor-Leste and Bougainville (Papua
New Guinea) have shown that tafenoquine containing
regimens for 3 days caused less relapses than a prima-
quine regimen of 22.5 mg/d for 14 days when adminis-
tered as terminal prophylaxis up to a follow up of 1
year. In addition to primaquine or tafenoquine, all
received doxycycline as the primary prophylactic agent
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ences of relapses between the primaquine treated and
tafenoquine treated groups apart from the subset return-
ing from Timor-Leste who received the lowest dose of
tafenoquine (200 mg/d for 3 days) that had less relapses.
Authors could not explain this discrepancy. However, it
was noted that some time after the trial ended, the
recommended dose of primaquine was raised to 30 mg/
d and with that, the relapse rates were further reduced.
Kitchener et al. [92] assessed the efficacy of an
extended course of tafenoquine in treating individuals
with relapsing vivax malaria who were initially treated
with primaquine (22.5 mg/d for 14 days) plus standard
chloroquine treatment. Twenty-seven individuals (of
Australian defense forces returning from deployment in
the areas mentioned previously) were offered tafeno-
quine 200 mg base for 3 days and 200 mg weekly for 8
weeks subsequently. They were followed up for six
months. There was only one relapse in this group,
which already had treatment failure with primaquine at
a dose of 22.5 mg daily. The tafenoquine-based long-
term regimen had a cure rate of 96% in this study.
Tafenoquine is probably the most extensively studied
compound showing hope of replacing primaquine in
future. It has demonstrated efficacy at least comparable
to primaquine in regimens of radical cure as well as in
terminal prophylaxis. However, the pharmacodynamics
of tafenoquine action on P. vivax is still not clear (e.g.,
the reason for a lower dose to be more effective than a
higher dose in terminal prophylaxis). All the trials which
compared tafenoquine against primaquine had done so
for a lower dose of primaquine than what is recom-
mended now. There may not be any advantage of tafe-
noquine had they compared it with a 30 mg/d course of
primaquine. The issue of haemolysis with G6PD defi-
cient individuals still remains a risk with tafenoquine.
All participants were cleared as non-G6PD deficient
prior to enrolment in the trials and the safety of tafeno-
quine against haemolysis is unknown. Probably the only
potential advantage tafenoquine carries is its ability to
e n s u r eab e t t e rc o m p l i a n c ew i t ht h e r a p ya st h et r e a t -
ment course can be shortened to three days.
Conclusions
The conclusions of this review as per current evidence
on primaquine are as follows;
a) Primaquine is efficacious for its current suggested
indications in relation to vivax malaria, namely; causal
prophylaxis (in special circumstances), terminal prophy-
laxis, and radical cure. It is the only licensed drug in use
against the intra-hepatic forms (schizonts and hypno-
zoites) of P. vivax but its efficacy is highly dependent on
the concurrent administration of a blood schizontocidal
agent. The most established drug in this regard is
chloroquine. The currently recommended dose against
vivax malaria is 0.5 mg/kg/d not exceeding 30 mg/d for
14 days for radical cure according to the CDC guide-
lines. However, WHO still recommends a lower dose
except for Oceania and Southeast Asia. We feel that the
evidence supports the use of the higher dose in prevent-
ing treatment failure in other regions as well.
b) G6PD deficiency state can cause severe haemolysis
with primaquine and it is a barrier against the wide-
spread use of the drug. Since its prevalence and severity
varies with geographical location as well as ethnic origin
of populations, it is difficult to propose universal guide-
lines in this regard. It is recommended that local gov-
ernments in endemic areas make a conscious effort to
quantify the prevalence of G6PD deficiency as it will
have a major effect on the control of vivax malaria.
Qualitative assessment with fluorescent testing may be
cost effective in this regard. Other side effects, such as
methaemoglobinaemia and gastrointestinal side effects,
did not pose a serious threat to health in clinical studies.
c) Resistance to primaquine is a doubtful entity. Most
cases of so-called ‘resistance’ might have been averted with
a higher dose of primaquine. The validity of reports is con-
taminated by errors in trial design, risk of re-infection,
inadequate dosing and unsupervised treatment. Further-
more, primaquine does not act in isolation and resistance
to it (if any) has to be defined in relation to the concur-
rently administered blood schizontocidal agent as well.
d) Artemisinin based therapies are a successful alter-
native in areas of chloroquine resistance against vivax
malaria. However primaquine in high doses has to be
administered concurrently to avert relapses. A few trials
in Southeast Asian region show that primaquine in high
doses is safe, well tolerated and efficacious in preventing
parasitaemia up to 28 days since initiation of therapy in
combination with artemisinins.
e) Tafenoquine is a drug with promise as an alterna-
tive to primaquine. However, its only advantage over
primaquine may be the shorter duration of treatment.
Neither its effect in relation to G6PD deficiency, nor its
efficacy compared with currently recommended treat-
ment, has been established. Further studies are needed
in this regard.
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